Sign in
Taking peoplePhase 3

REGN7508 and REGN9933 to prevent blood clots in people with a PICC line

Tests REGN7508 and REGN9933 against placebo for preventing venous thromboembolism in people with a PICC.

Key facts

Who runs it
Regeneron Pharmaceuticals
Where
Georgia, Greece, and Spain10 sites in 3 countriesChoose a country to see its sites
Registry title
Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)
Status
Recruiting
Phase
Phase 3
People taking part
1,908 people, planned
Started
7 Sept 2026
Expected to end
18 Sept 2029
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • REGN7508
  • REGN9933
  • Placebo
Record updated
29 September 2026

Who can take part

The trial is looking for people aged 15 years or older who are getting a PICC, a thin tube put into an arm vein to receive medicines. It tests whether REGN7508 or REGN9933 prevents blood clots, compared with placebo.

Age
15 years and older
Sex
All sexes
Disease stage
People getting a PICC for medicines given into a vein, such as chemotherapy, antibiotics or TPN (feeding through a vein). Daily activity level must be ECOG 3 or better, or a similar level.
Earlier treatment
People cannot join if they already have a central vein catheter, or a catheter in the spine or epidural space, during screening.
Biomarker or test result
INR and aPTT blood clotting tests no more than 25% above the upper limit. Body weight at least 40 kg (88 lb).
Main reasons for not taking part
  • Earlier blood clot in the arm or chest veins on the side where the PICC will go
  • Acute leukemia, myelodysplastic syndrome, or myelofibrosis
  • Cancer of the gut, food pipe, urinary or genital organs that has not been removed by surgery
  • Brain tumor or cancer spread to the brain, now or in the past
  • Major heart or blood vessel event in about the past 30 days
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • Is undergoing PICC placement for Intravenous (IV) administration of clinically indicated medications, including chemotherapy, antibiotics, TPN, and/or other indications as described in the protocol
  • Has Eastern Cooperative Oncology Group Performance (ECOG) Status ≤3 or equivalent functional status as described in the protocol
  • Has International Normalization Ratio (INR) and aPTT values no more than 25% above the upper limit as described in the protocol
  • Weighs at least 40 kg during the screening period

Who cannot take part

  • Has a history of prior venous thrombosis in the arm and/or ipsilateral thoracic central veins in which the PICC is to be placed
  • Has any major cardiovascular event within approximately the past 30 days prior to study administration
  • Has acute leukemia, myelodysplastic syndrome, or primary and secondary myelofibrosis
  • Has unresected luminal gastrointestinal (GI) (including esophageal) or unresected genitourinary (GU) malignancy
  • Has current or history of known brain tumors or brain metastases
  • Pre-existing central venous catheter or indwelling spinal or epidural catheter during the screening period; Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Venous thromboembolism

This trial is currently available in Georgia.

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have a tube placed in a vein to receive treatment (called Peripherally Inserted Central Catheter [PICC]). Patients with PICCs have a higher risk of getting blood clots which can block the veins (this is called Venous Thromboembolism [VTE]) and lead to serious health problems or be life threatening.

Read full original descriptionShow less

The aim of the study is to see how well REGN7508 and REGN9933 prevent blood clots compared to placebo after PICC placement and to see if these medications cause certain types of bleeding.

The study is looking at several other research questions, including:

* What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects) * If the study drugs affect the ability of the blood to clot normally

The 3 groups in the trial

  • REGN7508Treatment being tested
  • REGN9933Treatment being tested
  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Master Protocol for a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, for Prophylaxis of Venous Thromboembolism in Participants With a Peripherally Inserted Central Catheter (PICC) (ROXI-PEAK)
Plain-language title
REGN7508 and REGN9933 to prevent blood clots in people with a PICC lineGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 19 November 2026.
Criteria questions
Built from NCT07697599, who can take part
Record updated
29 September 2026